Also known as Viibryd
Vilazodone (United States trade name Viibryd) is a serotonergic antidepressant developed by Clinical Data for the treatment of major depressive disorder. The chemical compound was originally developed by Merck KGaA (Germany). By 2009 two phase III clinical trials with positive results had been completed. Vilazodone was approved by the FDA for use in the United States to treat major depressive disorder on January 21, 2011.Source: Wikipedia
Patients are most commonly prescribed vilazodone to treat rabies, blastomycosis, west nile virus, and pick disease.